Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

National Intersectoral MHPSS Emergency Preparedness and Response Plan: In the Context of the Risk of War on Lebanon

 
In response to the escalating situation and war on Lebanon, the Ministry of Public Health (MoPH) has developed and is currently implementing with all stakeholders the:
“National Intersectoral MHPSS Emergency Preparedness and Response Plan: In the Context of the Risk of War on Lebanon "

Developed through a collaborative approach by the National Mental Health Programme (NMHP) with the support of the World Health Organization, UNICEF, and all MHPSS Stakeholders (please refer to the action plan for a full list), this comprehensive plan outlines a proactive approach to anticipating, mitigating, and responding to the psychosocial impacts by focusing on early intervention and support to minimize the adverse effects on individuals, healthcare personnel and communities. It underscores the commitment of the MoPH and the NMHP to safeguard mental health and respond timely and effectively to the psychosocial needs of all populations residing in Lebanon during times of crisis while promoting their resilience.

Key Features of the Plan:
  • Continuity of MHPSS Services: The plan highlights actions to ensure the continued availability and accessibility of MHPSS services across Lebanon.
  • Assurance of Psychotropic Medications: The plan emphasizes ensuring the continuous supply and access to psychotropic medications to all old and new beneficiaries.
  • Communication and Messaging: The plan prioritizes the development and dissemination of key messages and tips on topics related to mental health and well-being that would promote community resilience.
  • Training and Capacity Building: The plan places a strong emphasis on training healthcare professionals and frontline responders in MHPSS principles and practices to provide effective support to service users and providers.
The MoPH is implementing this action plan with all stakeholders, including governmental bodies, local authorities and municipalities, non-governmental organizations, healthcare providers, frontliners, and the international community - Please do reach out if your organization is interested to join in implementing this crucial plan and working together to ensure the mental health and psychosocial support of Lebanon’s residents during times of adversity.

Kindly find a selection of valuable links below:
    ...
    22
    ...
ATC Name B/G Ingredients Dosage Form Price
N06DA52 EXENTAZIL G Donepezil - 10mg, Memantine - 14mg Capsule 3,117,715 L.L
R03DC03 LEUKOTRIS G Montelukast - 5mg 5mg Tablet 979,085 L.L
A02BC01 ULCAZAL G Omeprazole (sodium) - 40mg 40mg Injectable sterile lyophilised powder for solution 5,916,747 L.L
B03AA02 FERRATE G Ferrous fumarate - 20mg/ml (iron element) 20mg/ml Suspension 533,505 L.L
C07AA05 PROBETOL G Propranolol HCl - 10mg 10mg Tablet 126,705 L.L
C10AA08 PIVAL G Pitavastatin - 4mg 4mg Tablet 1,265,772 L.L
D11AX01 MINOXIDIL BAILLEUL G Minoxidil - 2% 2% Solution 2,839,539 L.L
J01DD04 LEBACEF G Ceftriaxone (sodium) - 1g 1g Injectable powder for solution 5,793,881 L.L
J01XX08 LINEZOLIDE STRAGEN G Linezolide - 600mg 600mg Tablet, coated 5,848,403 L.L
L01BC05 GEMNIL G Gemcitabine (HCl) - 200mg 200mg Injectable powder for solution 1,128,828 L.L
N06DA52 MEXAZIL XR 14/10 G Memantine HCl - 14mg, Donepezil HCl - 10mg Capsule 3,432,174 L.L
R03DC03 LEUKOTRIS G Montelukast - 4mg 4mg Tablet 783,268 L.L
A02BC01 OMEPRAL G Omeprazole - 20mg 20mg Powder for suspension 712,876 L.L
A07XA04 RACECADOTRIL ARROW G Racecadotril - 100mg 100mg Capsule 583,228 L.L
A11CC05 ALTO D 10.000 G Vitamin D3 - 10,000IU 10,000IU Capsule 895,895 L.L
B03AA02 FEOSTA G Ferrous fumarate - 200mg 200mg Tablet, film coated 682,160 L.L
C07AA05 APO-PROPRANOLOL G Propranolol HCl - 40mg 40mg Tablet, scored 356,118 L.L
C09DA01 LOSANET-H G Losartan potassium - 50mg, Hydrochlorothiazide - 12.5mg Tablet 395,474 L.L
D11AX01 ALOPEXY G Minoxidil - 50mg/ml 5% Solution 896,343 L.L
J01DD04 MEDAXONUM G Ceftriaxone (disodium) - 1g 1g Injectable powder for solution+diluent 438,093 L.L
L01BC05 GEMTABINE 200 G Gemcitabine HCl - 200mg 200mg Injectable lyophilised powder for solution 1,343,843 L.L
L04AD02 TACROGRAF 5 G Tacrolimus - 5mg 5mg Capsule 67,507,154 L.L
M03BC51 MUSCEROL 2 G Paracetamol - 450mg, Orphenadrine (citrate) - 35mg Tablet, scored 177,899 L.L
N02BE71 PYRETHAL G Paracetamol - 200mg, Phenobarbital - 20mg Suppository 147,183 L.L
S01GX08 ZALERG G Ketotifen - 0.25mg/ml 0.25mg/ml Drops solution 446,156 L.L
A02BC01 OMEPRAL G Omeprazole - 10mg 10mg Powder for suspension 890,776 L.L
A07XA04 RACECADOTRIL BGR G Racecadotril - 100mg 100mg Capsule 575,165 L.L
A11CC05 ALTUM-D3 G Vitamin D3 - 10,000IU 10,000IU Capsule 561,342 L.L
B03AA02 FEOSTA G Ferrous fumarate - 200mg 200mg Tablet, film coated 9,355,300 L.L
B05XA01 CHLORURE DE POTASSIUM PROAMP G Potassium chloride - 0.0746g/ml 0.0746g/ml Injectable concentrated solution 1,252,461 L.L
    ...
    22
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025